There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) and Elevance Health (ELV – Research Report) with bullish sentiments.
Iovance Biotherapeutics (IOVA)
In a report released yesterday, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Iovance Biotherapeutics, with a price target of $25.00. The company’s shares closed last Tuesday at $7.69.
According to TipRanks.com, Kusy has 0 stars on 0-5 stars ranking scale with an average return of -28.2% and a 22.5% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Karyopharm Therapeutics, and Mersana Therapeutics.
Iovance Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $22.44, a 221.0% upside from current levels. In a report issued on January 11, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
Elevance Health (ELV)
In a report released yesterday, Whit Mayo from SVB Securities reiterated a Buy rating on Elevance Health, with a price target of $580.00. The company’s shares closed last Tuesday at $478.52.
According to TipRanks.com, Mayo is a 4-star analyst with an average return of 5.6% and a 54.6% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Alignment Healthcare, and Privia Health Group.
Elevance Health has an analyst consensus of Strong Buy, with a price target consensus of $577.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOVA: